New Delhi, Dec 8 (NationPress) A novel antibody therapy designed to target both immune and cancer cells has exhibited remarkable promise in obliterating residual remnants of the lethal blood cancer known as multiple myeloma, as indicated by preliminary findings from a recent clinical trial.

The study involved 18 participants who experienced up to six treatment cycles with the antibody linvoseltamab. Remarkably, highly sensitive testing showed that none of the patients had any detectable signs of the disease, according to the research presented at the American Society of Hematology (ASH) annual meeting held in Orlando, US.

The initial results imply that linvoseltamab, a bispecific antibody, could enable patients to evade the necessity for bone marrow transplants, which usually entail rigorous and high-intensity chemotherapy.

This breakthrough also hints at a promising long-term enhancement of patients’ survival rates against this malignancy.

“These patients received cutting-edge and effective treatment early on, which eliminated 90 percent of their tumor,” stated lead investigator Dickran Kazandjian from the University of Miami’s Miller School of Medicine.

“Typically, patients in this situation would undergo high-dose chemotherapy followed by a transplant. Instead, we administered the drug linvoseltamab,” Kazandjian elaborated.

The research team described the outcomes thus far as “extremely impressive,” asserting that the elimination of lingering myeloma cells provides a hopeful outlook for the patients. Although the new therapy may keep the disease at bay for years, the possibility of its recurrence remains.

Multiple myeloma originates from immune cells known as plasma cells, which produce antibodies. The accumulation of these malignant cells disrupts normal blood cell function and causes significant damage. Currently, no established cure exists.

The researchers explained that linvoseltamab targets CD3, a protein located on T cells responsible for destroying cancer cells, and a second target, BCMA, a protein specific to multiple myeloma cells.

By connecting these two cell types, the antibody boosts the body’s immune response to combat the cancer.

In the trial, a few participants reported side effects, such as reduced levels of white blood cells termed neutropenia and upper respiratory infections; however, these incidents fell within an acceptable safety threshold, as noted by Kazandjian.

Given its current performance, researchers are optimistic that linvoseltamab could provide patients with more durable responses than traditional transplants, potentially leading to long-term disease management, described as a “functional cure.”